| Literature DB >> 28191312 |
C Maertens de Noordhout1, B Devleesschauwer2, L Gielens1, M H D Plasmans3, J A Haagsma4,5, N Speybroeck1.
Abstract
BACKGROUND: Utilities and disability weights (DWs) are metrics used for calculating Quality-Adjusted Life Years and Disability-Adjusted Life Years (DALYs), respectively. Utilities can be obtained with multi-attribute instruments such as the EuroQol 5 dimensions questionnaire (EQ-5D). In 2010 and 2013, Salomon et al. proposed a set of DWs for 220 and 183 health states, respectively. The objective of this study is to develop an approach for mapping EQ-5D utilities to existing GBD 2010 and GBD 2013 DWs, allowing to predict new GBD 2010/2013 DWs based on EQ-5D utilities.Entities:
Keywords: DW; EQ-5D; GBD2010; GBD2013; Mapping; Utilities
Year: 2017 PMID: 28191312 PMCID: PMC5292789 DOI: 10.1186/s13690-017-0174-z
Source DB: PubMed Journal: Arch Public Health ISSN: 0778-7367
Utilities by studies
| ID | Health states | Mean Utility study 1 | SD Utility study 1 | Mean Utility study 2 | SD Utility study 2 | DW2010 | DW2013 |
|---|---|---|---|---|---|---|---|
| 1 | Fractures, treated (long term) | 0.667 | 0.131 | 0.694 | 0.130 | 0.003 | 0.005 |
| 2 | Distance vision, mild | 0.826 | 0.154 | 0.004 | 0.003 | ||
| 5 | Anemia, mild | 0.813 | 0.138 | 0.005 | 0.004 | ||
| 8 | Amputation of toe | 0.650 | 0.127 | 0.008 | 0.006 | ||
| 11 | Asthma, controlled | 0.809 | 0.128 | 0.009 | 0.015 | ||
| 22 | Claudication | 0.644 | 0.177 | 0.016 | 0.014 | ||
| 29 | Stroke, long term mild | 0.550 | 0.168 | 0.021 | 0.019 | ||
| 37 | Disfigurement, level 1 with itch or pain | 0.639 | 0.177 | 0.029 | 0.027 | ||
| 47 | Fracture of foot bones (long term, without treatment) | 0.615 | 0.151 | 0.033 | 0.026 | ||
| 55 | Headache tension type | 0.530 | 0.169 | 0.350 | 0.204 | 0.040 | 0.037 |
| 60 | Amputation of both legs (long-term with treatment) | 0.304 | 0.244 | 0.051 | 0.088 | ||
| 77 | Injured nerves (short term) | 0.553 | 0.193 | 0.065 | 0.100 | ||
| 96 | Fracture tibia, patella (short term) | 0.389 | 0.170 | 0.087 | 0.050 | ||
| 107 | Musculoskeletal problems (arms moderate) | 0.474 | 0.173 | 0.114 | 0.117 | ||
| 111 | Severe wasting | 0.474 | 0.204 | 0.486 | 0.263 | 0.127 | 0.128 |
| 149 | Crohn’s disease | 0.455 | 0.200 | 0.225 | 0.231 | ||
| 155 | Parkinson’s disease moderate | 0.391 | 0.201 | 0.263 | 0.267 | ||
| 161 | Gout, acute | 0.193 | 0.212 | 0.293 | 0.295 | ||
| 174 | Severe chest injury (short term, with or without treatment) | 0.331 | 0.201 | 0.352 | 0.369 | ||
| 186 | Fracture of pelvis short term | 0.106 | 0.203 | 0.390 | 0.279 | ||
| 193 | Headache (migraine) | 0.548 | 0.194 | 0.433 | 0.441 | ||
| 200 | Rectovaginal fistula | 0.449 | 0.217 | 0.492 | 0.501 | ||
| 203 | Terminal phase, without medication (for cancers, end-stage kidney/liver disease) | 0.317 | 0.225 | 0.519 | 0.569 | ||
| 206 | AIDS cases (not received ARV treatment) | 0.360 | 0.228 | 0.547 | 0.582 | ||
| 214 | Traumatic brain injury (long-term consequences) | 0.200 | 0.257 | 0.625 | 0.637 | ||
| 219 | Multiple sclerosis (severe) | 0.144 | 0.198 | 0.707 | 0.719 | ||
| 220 | Schizophrenia, acute | 0.289 | 0.203 | 0.341 | 0.192 | 0.756 | 0.778 |
Description of the study population N (%) - Mean (SD)
| Study 1 ( | Study 2 ( | ||
|---|---|---|---|
|
|
| ||
| Age (years) – Mean (SD) | 29.6 (8.4) | 36.4 (12.5) | |
| Male | 57 (70.4) | 104 (26.5) | |
| Marital status | Married | 16 (20) | 153 (38.9) |
| Divorced | 7 (8.8) | 28 (7.1) | |
| Widower | 0 (0.0) | 5 (1.3) | |
| Separated | 0 (0.0) | 33 (8.4) | |
| Never been married | 57 (71.3) | 174 (44.3) | |
| Income level (in €) | <25 000 | 70 (17.8) | |
| 25 – 44 000 | 84 (21.4) | ||
| 45 – 52 000 | 98 (33.4) | ||
| >52 000 | 57 (14.5) | ||
| Not available | 84 (21.4) | ||
| Educational level | Primary | 1 (0.3) | |
| Lower secondary | 8 (2.0) | ||
| Higher secondary | 37 (9.4) | ||
| Bachelor | 156 (39.7) | ||
| Master or higher | 183 (46.6) | ||
| Not available | 2 (0.5) | ||
| Disease experience status | Yes | 121 (30.8) | |
Fig. 1Mapping utilities developed in pilot study 1 vs GBD 2010 DWs and GBD 2013 DWs. Grey dots = individual utility value , red dots = mean utility, grey line = linear regression line, black line = loess regression line
Ranking of the health states by studies
Red = higher than study-specific median for GBD 2010–2013 studies and lower than study-specific median for study 2
Green = lower than study-specific median for GBD 2010 - GBD 2013 studies and higher than study-specific median for study 2
Yellow = equal to study-specific median
Fig. 2Distribution of utilities derived in pilot study 2. Medians and ranges of the 27 utilities. Black dots represent outliers. Health state IDs are available in Table 2.
Fig. 3Mapping utilities developed in pilot study 2 versus GBD 2010 DWs and GBD 2013 DWs. Grey dots = individual utility value, red dots = mean utility, grey line = linear regression line, black line = loess regression line
Dimensions and levels frequency by study
| D1: Mobility | D2: Autonomy | D3: Daily activities | D4: Pain/discomfort | D5: Anxiety/ depression | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study 1 | Study 2 | Study 1 | Study 2 | Study 1 | Study 2 | Study 1 | Study 2 | Study 1 | Study 2 | |
| ID = 1 Fractures, treated (long term) | ||||||||||
| Level 1: None | 25% | 39% | 63% | 63% | 37% | 37% | 5% | 5% | 69% | 67% |
| Level 2: Weak | 62% | 44% | 31% | 31% | 49% | 49% | 78% | 78% | 28% | 28% |
| Level 3: Moderate | 11% | 17% | 6% | 6% | 12% | 12% | 15% | 15% | 1% | 6% |
| Level 4: Severe | 2% | 0% | 0% | 0% | 1% | 1% | 1% | 1% | 1% | 0% |
| Level 5: Extreme/Impossible | 0% | 0% | 0% | 0% | 0% | 0% | 1% | 1% | 0% | 0% |
| Mean | 1.91 | 1.78 | 1.43 | 1.33 | 1.78 | 1.61 | 2.16 | 2.19 | 1.35 | 1.39 |
| SD | 0.67 | 0.72 | 0.61 | 0.48 | 0.71 | 0.73 | 0.58 | 0.52 | 0.57 | 0.60 |
| ID = 55 Headache tension type | ||||||||||
| Level 1: None | 52% | 30% | 53% | 48% | 6% | 2% | 1% | 0% | 19% | 16% |
| Level 2: Weak | 37% | 24% | 30% | 14% | 32% | 10% | 12% | 6% | 47% | 18% |
| Level 3: Moderate | 10% | 18% | 14% | 30% | 51% | 34% | 56% | 20% | 28% | 34% |
| Level 4: Severe | 1% | 22% | 4% | 4% | 9% | 44% | 25% | 60% | 6% | 24% |
| Level 5: Extreme/Impossible | 0% | 6% | 0% | 4% | 2% | 10% | 6% | 14% | 0% | 8% |
| Mean | 1.60 | 2.50 | 1.68 | 2.02 | 2.69 | 3.50 | 3.22 | 3.82 | 2.22 | 2.90 |
| SD | 0.72 | 1.30 | 0.85 | 1.15 | 0.82 | 0.89 | 0.79 | 0.75 | 0.82 | 1.18 |
| ID = 111 Severe Wasting | ||||||||||
| Level 1: None | 14% | 28% | 26% | 42% | 6% | 25% | 46% | 23% | 11% | 19% |
| Level 2: Weak | 32% | 17% | 35% | 26% | 17% | 17% | 30% | 43% | 20% | 23% |
| Level 3: Moderate | 27% | 28% | 27% | 23% | 43% | 26% | 20% | 28% | 37% | 30% |
| Level 4: Severe | 27% | 19% | 12% | 6% | 30% | 25% | 5% | 6% | 27% | 23% |
| Level 5: Extreme/Impossible | 0% | 8% | 0% | 4% | 4% | 8% | 0% | 0% | 5% | 6% |
| Mean | 2.68 | 2.60 | 2.26 | 2.04 | 3.07 | 2.74 | 1.84 | 2.17 | 2.95 | 2.74 |
| SD | 1.02 | 1.11 | 0.98 | 0.88 | 0.93 | 1.10 | 0.91 | 0.68 | 1.06 | 0.99 |
| ID = 220 Schizophrenia | ||||||||||
| Level 1: None | 56% | 73% | 31% | 73% | 2% | 13% | 43% | 38% | 2% | 4% |
| Level 2: Weak | 16% | 8% | 22% | 10% | 7% | 6% | 22% | 21% | 1% | 4% |
| Level 3: Moderate | 19% | 10% | 35% | 12% | 17% | 17% | 15% | 13% | 10% | 10% |
| Level 4: Severe | 9% | 8% | 11% | 6% | 52% | 42% | 16% | 19% | 28% | 25% |
| Level 5 : Extreme/Impossible | 1% | 2% | 1% | 0% | 21% | 21% | 4% | 8% | 58% | 58% |
| Mean | 1.84 | 1.58 | 2.30 | 1.50 | 3.81 | 3.52 | 2.15 | 2.37 | 4.38 | 4.29 |
| SD | 1.09 | 1.07 | 1.07 | 0.92 | 0.94 | 1.28 | 1.25 | 1.37 | 0.90 | 1.05 |